REVIEW ARTICLE

Pharmaceutical Quality Control and Assurance in the 21st Century

Prajakta Dandekar, Mayur R. Dandekar, Prasana Putane

DattaMeghe College of Pharmacy, DattaMeghe Institute of Higher Education and Research, (DU), Sawangi (M), Wardha, Maharashtra, India.

Abstract

In the 21st century, the pharmaceutical industry faces dynamic and ever-evolving challenges that demand a robust commitment to quality control and assurance. This review article delves into the multifaceted landscape of pharmaceutical quality, highlighting plays' critical role in ensuring medication safety and efficacy. As the pharmaceutical world experiences profound shifts driven by technological advertisement, global supply chains, and regulatory updates this article offers an in-depth exploration of the key facets that define quality control and assurance in this era. Regulatory oversight has significantly transformed, with agencies such as the FDA and EMA adapting to keep pace with the industry's changing dynamics. We examine the current regulatory landscape, its impact on quality standards, and the growing emphasis on transparency and compliance. Advertisements in analytical techniques have revolutionized quality control, from mass spectrometry and nuclear magnetic resonance to sophisticated spectroscopy methods. This article explores these advanced tools and their contribution to product quality. Quality by design (QbD) principles have gained traction, advocating a proactive approach to quality control by integrating it into the product development process. We discuss the implications of QbD and its tangible benefits. Looking to the future, we predict emerging trends that will continue to shape pharmaceutical quality control and assurance technology such as blockchain and 3D printing are expected to play pivotal roles. In conclusion, this comprehensive review serves as a vital resource for professionals, researchers, and playmakers seeking a nuanced understanding of the ever-evolving terrain of pharmaceutical quality control and assurance. It emphasizes the critical importance of adapting to meet modern challenges and seizing opportunities for innovation in the pursuit of pharmaceutical excellence.

Key words: FDA, quality assurance, quality by design, quality control

INTRODUCTION

The pharmaceutical industries stand at a critical junction in the 21st century, where the confluence of science technology, and global interconnected has ushered in a New Era of pharmaceutical quality control and assurance as the world grapples with an array of health challenges and rising expectations for drugs safety and efficacy the importance of maintaining stringent quality standard has never been more pronounced. Historically, the pharmaceutical sector has been unwavering in its commitment to product quality.[1] In the early years of pharmaceutical production, quality control primarily revolved around physical inspections and limited testing. The 21st century has witnessed a radical transformation in this regard. Quality by design (QbD) principal advocates for integrating quality into the very fabric of pharmaceutical development. Through a combination of historical insights, contemporary practices, and future predictions, we navigate the intricate terrain of an industry where quality is not a mere aspiration but a mandate.[2]

CURRENT REGULATORY LANDSCAPE

The drug business works in a profoundly managed climate, and the administrative scene has undergone massive changes and variations in the 21st 100 years.

Address for correspondence:
Mayur R. Dandekar, DattaMeghe College of Pharmacy, DattaMeghe Institute of Higher Education and Research (DMIHER) (DU), Sawangi (Meghe), Wardha - 442 001, Maharashtra, India. Phone: +91 8605962737.
E-mail: mayurdandekar1727@gmail.com

Received: 02-07-2024
Revised: 11-09-2024
Accepted: 23-09-2024

Quality-based guidelines

The focal point of guidelines has moved from just stressing consistency to a quality-based approach. Administrative specialists, including the FDA and EMA, have embraced quality measurements that pressure the significance of steady and dependable quality in drug items. The quality-based guidelines plan to guarantee that each move toward the assembling and appropriation process lines up with predefined quality credits, from natural substance obtaining to bundling and dispersion.

Straightforwardness and information uprightness

The administrative scene in the 21st century likewise puts areas of strength for straightforwardness and information respectability. Specialists anticipate that drug organizations should keep a far-reaching and exact record, everything being equal, which incorporates assembling, testing, and quality control. This elevated spotlight on information uprightness guarantees that drug quality control rehearses are established in dependable information, diminishing the potential for blunders and guaranteeing predictable item quality.

Drug serialization and track-and-follow

To battle fake medications and upgrade discernibility, numerous administrative bodies have ordered drug serialization and track-and-follow frameworks. These frameworks include the special recognizable proof and following of individual medication items at each phase of the store network. Serialization is instrumental in guaranteeing that fake items do not enter the market and, thus, keeping up with drug quality and patient security.

Administrative adaptability and variation

The 21st-century administrative scene is portrayed by a more noteworthy level of adaptability and flexibility. Administrative bodies perceive that advancement in the drug business can outperform the improvement of new rules. Thus, they have taken on a defter methodology, able to work intimately with drug organizations to explore an unfamiliar area and integrate novel treatments into existing administrative structures. We investigate the high-level insightful methods, risk-based approaches, and imaginative quality control methodologies that are being embraced to fulfill the rigid quality guidelines requested by this changed administrative climate.[3]

ADVANCED ANALYTICAL TECHNIQUES

In the 21st 100 years, drug quality control and confirmation have been changed by an exceptional exhibit of cutting-edge scientific methods. These advancements not only empower drug organizations to guarantee item quality and consistency yet in addition work with the improvement of state-of-the-art treatments. This part dives into the complex scientific instruments that have reshaped the scene of drug quality control and affirmation. Mass Spectrometry: Mass spectrometry has turned into a foundation of drug investigation. It offers unrivaled capacities in recognizing and measuring compounds, both dynamic drug fixings (APIs) and pollution. Present-day mass spectrometers are profoundly delicate and can identify minute hints of substances, upgrading the capacity to keep up with the nature of drug items.[4]

In Figure 1 there are various Advanced analytical techniques are show.

Nuclear magnetic resonance spectroscopy

NMR spectroscopy assumes an urgent part in drug quality control. It gives a non-disastrous and exceptionally instructive method for breaking down the design, organization, and virtue of drug compounds. With the appearance of high-field NMR instruments, drug organizations can investigate complex particles with accuracy

X-beam crystallography

X-beam crystallography is instrumental in deciding the three-layered construction of glass-like compounds. It is broadly utilized in the drug business to guarantee the quality and trustworthiness of strong state types of drug substances.



Figure 1: Advanced analytical techniques

Nanotechnology in examination

Nanotechnology has acquainted novel methodologies with drug quality control. Nanoscale methods, for example, nanoparticle following examination (NTA), are utilized to portray and control the size, shape, and strength of nanoparticles, which are progressively utilized in drug conveyance frameworks.

Mass spectrometry

Mass spectrometry is a strong scientific procedure for the recognizable proof and evaluation of drug compounds. It assumes a pivotal part in evaluating the virtue of dynamic drug fixings (APIs) and completed items. Fluid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry are ordinarily utilized in drug examination.

Information examination and computerized reasoning (artificial intelligence [AI])

The incorporation of information investigation and Al has changed how drug organizations dissect and decipher information. By breaking down information progressively, drug organizations can recognize and resolve quality issues before they heighten, guaranteeing that the items arriving at patients are of the greatest quality. In the accompanying areas of this survey, we dig into the pragmatic uses of these high-level scientific procedures and their part in forming the scene of drug quality control in the 21st 100 years.[5]

There are various key elements of pharmaceutical quality control and quality assurance mention in Table 1.

PROCESS VALIDATION AND CONTINUOUS IMPROVEMENT

In the 21st century, pharmaceutical quality control has shifted its focus from merely inspecting the finished product to ensuring quality throughout the entire product lifecycle. This transition has made process validation and continuous improvement integral components of pharmaceutical quality assurance. This section delves into the importance of process validation and the principle of continuous improvement in the pharmaceutical industry.

Importance of process validation

Process validation is a systematic approach to ensuring that pharmaceutical manufacturing processes consistently produce products of the desired quality. It is a critical element of pharmaceutical quality control, as it not only verifies the manufacturing process but also ensures that any changes or modifications are thoroughly assessed before implementation three stages of process validation include prospective validation, concurrent validation, and retrospective validation.

Risk-based approach to validation

In the modern era, the pharmaceutical industry has adopted a risk-based approach to validation. This method identifies and prioritizes critical quality attributes and critical quality attributes (CQAS) and critical process parameters that have the most significant impact on product quality by focusing validation efforts on these critical elements, the pharmaceutical can ensure that quality is maintained with maximum efficiency.

Six Sigma and lean manufacturing

Concepts such as Six Sigma and lean manufacturing are widely adopted in the pharmaceutical industry to achieve process efficiency and quality control. These methodologies focus on eliminating defects. Reducing variation, and optimizing processes, ultimately enhancing product quality.[6]

Real-time release testing (RTRT)

RTRT is a modern approach that allows for the release of pharmaceutical products in real time based on in-process testing data rather than relying solely on end-products while ensuring quality and safety. The ability to identify and correct issues in real time minimizes the risk of production

Table 1: Key elements of pharmaceutical quality control and quality assurance

Aspect	Pharmaceutical quality control	Pharmaceutical quality assurance
Definition	Ensures the products meet predefined quality standards during manufacturing and distribution.	Ensures that the processes produce products meeting established quality standards.
Key focus	Inspection, testing, and verification of product quality.	Proactive planning, implementation, and continuous improvement of quality processes.
Role in production	Detects and rectifies defects in finished products through testing and inspection.	Prevents defects by defining standards, protocols, and quality management systems.
Reactive versus proactive	The reactive approach to identifying and rectifying	A proactive approach to preventing defects

delays and costly recalls by integrating these practices pharmaceutical companies can align themselves with the evolving landscape of pharmaceutical quality control in the 21st century, delivering safe and effective products to patients consistently.[7]

QbD

In the 21st 100 years, quality by plan, or QbD, has developed into a weighty strategy for drug quality confirmation and control. It means a change in perspective in the field by focusing on quality in the assembling and medication improvement processes. The establishments, benefits, and uses of QbD in the drug business are analyzed in this segment.

Standards of QbD

QbD is a deliberate interaction that integrates quality contemplations into the whole drug item improvement life cycle, from detailing to assembling. It puts serious areas of strength for on planning frameworks and cycles proactively to ensure steady item quality. The objective of QbD is to appreciate how fabricating techniques, unrefined components, and basic quality ascribes (CQAs) influence the presentation of the completed item.

Advantages of QbD

Embracing QbD gives many benefits. Accordingly, the assembling system turns out to be more solid and successful, bringing down the chance of clump disappointments and the necessity for extended testing. Quality by Design (QbD) works on the consistency of item quality and well-being by underlining the comprehension and control of interaction factors. By advancing the examination of state-of-the-art strategies and materials, it additionally cultivates development.

Applications in medication advancement

QbD is utilized at each phase of the medication advancement process, from process increasing to detailing improvement. It makes it conceivable to make drug plans that fulfill wanted item profiles. Quality by Plan (QbD) makes it simpler to advance assembling processes during process improvement. It is additionally valuable in the advancement of scientific strategies, ensuring the exact testing of value ascribes.[8]

Meaning of value by plan (QbD)

QbD is a methodology that stresses the deliberate plan and improvement of drug items and assembling cycles to accomplish predefined quality targets. It incorporates logical grasping, risk appraisal, and hearty interaction control all through the item lifecycle.[9]

ICH Q8, Q9, and Q10

QbD standards are typified in a few Global Gathering on Harmonization (ICH) rules, including ICH Q8 (Drug Improvement), ICH Q9 (Quality Gamble TheExecutives), and ICH Q10 (Drug Quality Framework). These rules give an organized structure to executing QbD.

Benefits of QbD

The QbD approach offers a few benefits, including improved item quality, decreased chance of deviations, and the capacity to pursue information-driven choices. It likewise advances adaptability in assembling cycles and cultivates development.[10]

Future headings

The fate of QbD might include a more prominent incorporation of ongoing quality observing, computerization, and digitalization. These progressions can additionally refine the proactive and information-driven nature of QbD. A key change in the reasoning behind drug quality control and confirmation is addressed by QbD. It energizes a culture of development and consistent improvement, going past basic consistency. Drug organizations in the 21st century are better situated to fulfill the continually rising needs for drug items that are protected, powerful, and of the greatest quality by proactively planning quality into items and cycles.[11]

PHARMACOVIGILANCE AND POST-MARKET SURVEILLANCE

Meaning of chance-based approaches

Risk-based approaches in drug quality control include recognizing, assessing, and taking a chance that can influence item quality, patient security, and administrative consistency. The center rule is to designate assets and spotlight endeavors on regions with the most elevated risk.[12]

Ceaseless gamble observing

Rather than a one-time risk evaluation, risk-based approaches call for nonstop gamble checking all through the item lifecycle. This empowers convenient reactions to arising dangers and quality deviations.[13]

Advantages of chance-based approaches

The essential advantage of hazard-based approaches is the improvement of assets and endeavors. By focusing on high-risk regions, drug organizations can improve item

quality, security, and consistency while staying away from superfluous expenses and postponements.[14]

Future headings

The fate of hazard-based approaches might imply a more prominent incorporation of information examination, computerized reasoning, and continuous quality observing. The point is to additionally refine risk evaluation and dynamic cycles. In the pharmaceutical industry of the twenty-first century, pharmacovigilance and post-market surveillance are essential for guaranteeing the quality and safety of products after they are administered to patients. These procedures go above and beyond simple production and packaging; they also actively track patients' actual experiences with medications.[15] Their ongoing development is essential to spotting possible safety concerns and taking prompt, thorough action.[16]

INVENTORY NETWORK THE EXECUTIVES

The drug business' utilization of production network executives has changed essentially in the 21st 100 years. The creation and appropriation of drugs have become more globalized, which has expanded the intricacy, network, and difficulties faced by the store network. The importance, challenges, and changing strategies in drug store network executives are analyzed in this segment.

Significance of production network the executives

Drug item accessibility, quality, and security rely vigorously upon an effective inventory network for the executives. Patients anticipate that their medications should be followed through on time, and drug organizations depend on a protected and powerful inventory network to guarantee the nature of their items.

Collaboration and risk sharing

It is imperative that pharmaceutical companies, regulatory bodies, and other supply chain stakeholders work together. Coordinating responses and exchanging information about possible hazards improves the group's capacity to deal with problems successfully.[16]

Risk the executives in-store network

Inventory network risk the executives implies recognizing, evaluating, and relieving gambles that could affect item quality or disturb inventory network coherence. Dangers can incorporate interruptions because of catastrophic events, transportation issues, administrative changes, and international variables.[17]

Drug cold chain

Numerous drug items, such as immunizations, biologics, and certain anti-microbials, are profoundly delicate to temperature varieties. The drug cold chain is a specific inventory network intended to keep up with exact temperature control all through the transportation and capacity of these items.

Continuous checking and IoT

The utilization of constant checking and Internet of Things (IoT) gadgets has essentially improved the straightforwardness and perceivability of the inventory network. These advances consider following item conditions as well as natural boundaries, which is especially significant for drug cold chain the board.

Blockchain innovation

Blockchain innovation is arising as a device for improving straightforwardness and recognizability in the drug store network. It gives a protected and permanent record of exchanges, making it conceivable to confirm the genuineness and provenance of drug items.

Joint effort and chance sharing

A joint effort among drug organizations, administrative offices, and different partners in the production network is pivotal. Sharing data about possible dangers and planning reactions upgrades the aggregate capacity to successfully address difficulties. The pharmaceutical supply chain is a dynamic, ever-evolving system that is impacted by global shifts, regulatory changes, and technological breakthroughs. Supply chain management strategies are always evolving as the industry tries to strike a balance between the need to maintain product quality and the demand for efficient supply chain operations. Supply chain management is still a vital component of pharmaceutical quality assurance and control in the twenty-first century, guaranteeing patients receive their medications in a timely and safe manner. Vaccines and biologics are just two examples of the many pharmaceutical products that need careful temperature control all the way through the supply chain. To preserve the quality and efficacy of temperature-sensitive pharmaceuticals, controlled storage, and transportation are facilitated by the pharmaceutical cold chain.[18]

Describe the eQMS in Figure 2.

CASE STUDIES AND EXAMPLES

Insights into the 21st century practical implementation of pharmaceutical quality control and assurance can be gained from real-world case studies and examples. These examples

Figure 2: The figure of eQMS

provide concrete insights and demonstrate the ongoing evolution of the pharmaceutical industry by illuminating the successes as well as the challenges faced by these companies.

Real-world data in pharmacovigilance

Examples of how pharmacovigilance uses real-world data include finding adverse events that were missed in clinical trials. As a result, safety issues have been identified, and post-market surveillance has been improved.

Valsartan contamination

The identification of carcinogenic contaminants in specific lots of the angiotensin receptor blocker Valsartan prompted extensive product recalls and regulatory investigations. It emphasized how crucial strict supply chain management and quality assurance are.[19]

Significance of pharmacovigilance

Pharmacovigilance is irreplaceable in recognizing and surveying potential well-being concerns related to drug items. It supports the early discovery of unfriendly occasions, which can prompt opportune intercessions and forestall mischief to patients.

Administrative commands

Administrative offices such as the U.S. Food and Medication Organization and the European Drugs Office require drug organizations to have powerful pharmacovigilance frameworks set up. These frameworks incorporate the assortment, investigation, and announcing of unfavorable occasions related to their items.

Certifiable information incorporation

The utilization of certifiable information (RWD) from different sources, for example, electronic wellbeing records, patient reports, and wearable gadgets, has extended the extent of pharmacovigilance. RWD offers a more extensive and more exact point of view on the security and viability of drug items in certifiable settings.

Signal location and investigation

Pharmacovigilance includes signal location, which is the most common way of distinguishing potential security worries from aggregated information. Progressed investigation and information mining methods are utilized to reveal patterns and examples that might show well-being issues.[28]

Worldwide joint effort

Global joint effort in pharmacovigilance has become progressively significant, as security concerns frequently rise above public boundaries. Associations such as the World Wellbeing Association (WHO) elevate worldwide information sharing to improve security reconnaissance.

Difficulties and future bearings

Despite headways, challenges remain, including the requirement for more productive sign location strategies and the reconciliation of different information sources. Future headings might incorporate robotization and man-made consciousness to upgrade the effectiveness of pharmacovigilance processes.

The changing field of pharmaceutical quality assurance and control is illustrated by these case studies and illustrations. They emphasize how important it is to have transparent, proactive quality management as well as strong regulatory oversight in a field where patient safety is crucial. Pharmaceutical professionals can learn from and get ideas for their own quality control procedures and decision-making processes by examining these real-world scenarios.[20]

FUTURE TRENDS

Pharmaceutical quality assurance and control are expected to have a dynamic future, driven by new trends that adapt to changing patient needs, technological advancements, and global issues. Pharmaceutical companies must comprehend and adjust to these trends if they are to pursue ongoing

innovation and improvement. Observe the following important future trends:

AI and digitalization

Pharmaceutical quality control is about to undergo a revolutionary change thanks to the integration of digital technologies and AI. Predictive maintenance, real-time quality monitoring, and data analytics can all benefit from AI. Digital platforms can also be used to improve the visibility and traceability of the supply chain.

Pharmaceutical 3D printing

With the ability to create customized medication formulations and on-demand production, 3D printing is anticipated to be extremely important to the pharmaceutical sector. Keeping 3D-printed medications consistent and of high quality will be a top concern.[21]

Biosimilars and biologics

To prove that biosimilars and biologics are comparable to reference products, strict quality control will be necessary as these products expand in the pharmaceutical market. Strict quality standards and analytical techniques will be necessary.[22]

Environmental and sustainability initiatives

Environmental and sustainability initiatives are being adopted by pharmaceutical companies at an increasing rate. This covers cutting waste, minimizing the environmental impact of pharmaceutical production, and sourcing raw materials sustainably. Standards and procedures for quality control may be impacted by sustainable practices.

Remote audits and inspections

Technological progress in virtual and remote technologies could increase remote audits and inspections, allowing regulatory bodies to evaluate pharmaceutical facilities even when they are not physically present.[23]

Real-world data integration

Post-market surveillance and safety monitoring will be improved through the integration of real-world data from wearable technology, electronic health records, and patient-reported outcomes.

Computerized twins

The idea of computerized twins, where virtual models of assembling cycles and items are made, is getting some forward momentum. These computerized reproductions empower ongoing checking and forecast, working with quick reaction to deviations in assembling.

AI

Man-made consciousness and AI are set to reform quality control. Prescient calculations can expect quality issues before they happen, lessening the occurrence of deformities and upgrading process productivity.[24]

Customized medication

The coming of customized medication requests a change in quality control rehearses. Tweaked drug details and treatments require custom-made quality evaluations and create some distance from one-size-fits-all methodologies.

Decentralized assembling

Progresses in 3D printing and limited-scope fabricating advances empower decentralized creation, diminishing the intricacy of the store network. Quality control in this setting will zero in on nearby, on-request creation.[27]

Blockchain in-store network

The drug inventory network will see the inescapable reception of blockchain innovation. Blockchain guarantees straightforwardness and discernibility, which is fundamental for confirming the realness and nature of drug items.[25]

Quality and cell treatments

As quality and cell treatments become more pervasive, quality control will adjust to the exceptional difficulties of these original medicines. Vigorous scientific techniques and quality guidelines intended for these treatments will be created.

Maintainability and ecological obligation

Drug organizations will escalate their obligation to supportability, zeroing in on eco-accommodating assembling processes, green bundling, and moral obtaining of unrefined components. These manageable practices will affect quality control guidelines.[26]

High-level sensors and IoT

The expansion of cutting-edge sensors and the Web of Things (IoT) gadgets will offer constant information assortment and examination, upgrading the accuracy of value control processes.[29]

Worldwide cooperation

The eventual fate of drug quality control and confirmation is invigorating and dynamic, with innovation, development, and cooperation at its center. The business' obligation to guarantee the best expectations of item quality and well-being will stay relentless, even as it adjusts to meet the developing necessities of patients and the difficulties of a quickly changing medical services scene.[30]

Author Contribution Statement

Mr. Yash R. Thakare conceptualized and gathered the data regarding this work. Prof. Shivani Makhijanianalyzed the data and necessary inputs were given for designing the methodology and results leading to final manuscripts.

CONCLUSION

Pharmaceutical quality assurance and control have changed in the 21st century in response to a dynamic environment created by alterations in regulations, global challenges, and technological advancements. These advancements have been fueled by the pharmaceutical industry's unwavering dedication to patient safety, product quality, and innovation. On considering the various facets examined in this review, several significant insights and deductions become apparent. Patient-Centric Focus – Pharmaceutical quality assurance and control continue to revolve around patient safety and satisfaction. The pharmaceutical industry is steadfast in its commitment to guaranteeing that each drug satisfies the highest quality requirements. Regulatory Evolution – The world's regulatory agencies have adjusted to the challenges posed by new treatments, international supply chains, and changing quality requirements. The focus on risk-based methodologies, QbD, and harmonization shows a cooperative effort to guarantee quality and safety. Technological Advancements – Pharmaceutical companies are now able to precisely maintain product quality thanks to the adoption of sophisticated analytical techniques such as mass spectrometry, NMR, and data analytics. Technologies such as blockchain and 3D printing have the potential to completely change pharmaceutical production and quality assurance. Continuous Improvement – There is a culture of continuous improvement as a result of the integration of risk-based methodologies and quality design principles. Pharmaceutical firms are becoming more adept at addressing issues with quality and preserving product uniformity. Supply Chain Complexity – The worldwide pharmaceutical supply chain presents a challenge as well as an opportunity. Although it saves money, there are risks to quality and supply disruptions for the industry. Traceability and strong supply chain management are crucial. Pharmacovigilance and Real – World Surveillance – The focus on post-market surveillance and pharmacovigilance highlights the industry's dedication to tracking product safety after release. Early detection of safety issues is becoming more and more possible thanks to real-world data and technology.

REFERENCES

1. Geyer AR, Sousa VD, Silveira D. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections. PLoS One 2018;13:e0202084.
2. Campbell HR, Lodder RA. A brief review of FDA's Novel tools for ensuring pharmaceutical quality in the human drug supply chain. CIC Pharm Sci 2021;1:1-0.
3. Aziza F. Comparison review of two regulatory agencies regulation: Therapeutic Goods Administration (TGA) and the European Medicine Agency (EMA) in relation to Good Manufacturing Practice (GMP) guideline. Majalah Farmaseutik 2021;17:243-8.
4. Burke SP, Stratton K, Baciu A, editors. The Future of Drug Safety: Promoting and Protecting the Health of the Public. United States: National Academies Press; 2007.
5. Tanaka K, Saito R, Matsuhama M, Miyazaki S. Comparative study of general notices in pharmacopoeias in Japan, the United States, and Europe. Chem Pharm Bull (Tokyo) 2023;71:41-51.
6. Zagalo DM, Sousa J, Simões S. Quality by Design (QbD) approach in marketing authorization procedures of non-biological complex drugs: A critical evaluation. Eur J Pharm Biopharm 2022;178:1-24.
7. Guideline IC. Q9-Quality Risk Management. In: Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2012.
8. World Health Organization. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva: World Health Organization; 2004.
9. U.S. Food and Drug Administration. Food and Drug Administration Safety and Innovation Act (FDASIA). Maryland: Food and Drug Administration; 2012.
10. Lægreid P, Roness PG, Rubecksen K. Controlling regulatory agencies. Scand Political Stud 2008;31:1-26.
11. Maggetti M. The role of independent regulatory agencies in policy-making: A comparative analysis. J Eur Public Policy 2009;16:450-70.
12. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv 2018;15:737-58.
13. Quirk PJ. Industry Influence in Federal Regulatory Agencies. United States: Princeton University Press; 2014.
14. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
15. Ciociola AA, Cohen LB, Kulkarni P, Kefalas C,

Buchman A, Burke C, *et al.* How drugs are developed and approved by the FDA: Current process and future directions. Am J Gastroenterol 2014;109:620-3.
16. ICH Harmonised Tripartite Guideline. ICH Q9: Quality Risk Management. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005.
17. ICH Harmonised Tripartite Guideline. ICH Q10: Pharmaceutical Quality System. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2009.
18. U.S. Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach: Progress and Opportunities. Maryland: Food and Drug Administration; 2011.
19. European Medicines Agency. Quality Guidelines. Amsterdam: European Medicines Agency; 2018.
20. World Health Organization. WHO Guidelines on Good Manufacturing Practices (GMP). WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: World Health Organization; 2016.
21. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, *et al.* Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-97.
22. Patterson A. Pharmaceutical supply chain integrity. Pharm Eng 2017;37:28-34.
23. Elamin AI. Application of Quality by Design (QbD) in pharmaceutical formulations. World J Pharm Sci 2017;5:38-45.
24. FDA, CDER Science and Research. Advancing Regulatory Science at FDA: A Strategic Plan. Maryland: Food and Drug Administration; 2018.
25. Foschi M, Marziale M, Biancolillo A. Advanced analytical approach based on combination of FT-IR and chemometrics for quality control of pharmaceutical preparations. Pharmaceuticals 2022;15:763.
26. European Medicines Agency. Reflection Paper on Statistical Methodology for the Comparative Assessment of Quality Attributes in Drug Development. Amsterdam: European Medicines Agency; 2019.
27. Khan AH, Aziz HA, Palaniandy P, Naushad M, Cevik E, Zahmatkesh S. Pharmaceutical residues in the ecosystem: Antibiotic resistance, health impacts, and removal techniques. Chemosphere 2023;339:139647.
28. FDA. Pharmaceutical Quality/CMC. FDA's Role in Ensuring the Quality of Generic Drugs. Maryland: Food and Drug Administration; 2020.
29. Zhang J, Thakkar R, Zhang Y, Maniruzzaman M. Structure-function correlation and personalized 3D printed tablets using a quality by design (QbD) approach. Int J Pharm 2020;590:119945.
30. Kellum A, Guilfoil L. Quality by design and the 21st century CMC. PDA J Pharm Sci Technol 2018; 72:360-5.

Source of Support: Nil. **Conflicts of Interest:** None declared.